1. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
   Isao Murakami et al, 2023, Journal of Gynecologic Oncology CrossRef
2. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature
   Chifumi Ohyagi-Hara et al, 2015, Archives of Gynecology and Obstetrics CrossRef
3. Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma
   MASAKAZU SATO et al, 2016, Molecular and Clinical Oncology CrossRef
4. Menstrual cyclic change of metastin/GPR54 in endometrium
   Tsukasa Baba et al, 2015, Medical Molecular Morphology CrossRef
5. Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
   Junyu Chen et al, 2022, Frontiers in Oncology CrossRef
6. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women
   Bo-er Shan et al, 2013, Archives of Gynecology and Obstetrics CrossRef
7. Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review
   Teska Schuurman et al, 2021, Cancers CrossRef
8. Medroxyprogesterone derivatives from microbial transformation as anti-proliferative agents and acetylcholineterase inhibitors (combined in vitro and in silico approaches)
   Sharifah Nurfazilah Wan Yusop et al, 2020, Steroids CrossRef
9. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer
   Satoshi Tamauchi et al, 2018, Journal of Obstetrics and Gynaecology Research CrossRef
10. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer
    Olga V. Novikova et al, 2021, Gynecologic Oncology CrossRef
11. Updates on conservative management of endometrial cancer in patients younger than 45 years
    Sergio M. Lucchini et al, 2021, Gynecologic Oncology CrossRef
12. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
    Raya Faigenbaum et al, 2013, Oncotarget CrossRef
13. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women’s health at the university of Tuebingen
    Jürgen Andress et al, 2021, Archives of Gynecology and Obstetrics CrossRef
14. Successful fertility preservation in stage II endometrial carcinoma with long-term progestin therapy: A case report
    Yuki Kashihara et al, 2024, Gynecologic Oncology Reports CrossRef
15. Fertility-sparing management for endometrial cancer: review of the literature
    Simone GARZON et al, 2021, Minerva Medica CrossRef
16. Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
    Qing Zhang et al, 2017, Oncotarget CrossRef
17. 11β-Hydroxymedroxyprogesterone
    Sharifah Nurfazilah Wan Yusop et al, 2016, IUCrData CrossRef